After wrapping up a very eventful October, HDAX is pleased to share its recognition by various Industry-supported pitch competition.
Lab Central Ignite Golden Ticket – September 19 2023
COO and Cofounder, Dr. Pimyupa Manaswiyoungkul, won the prestigious Golden Ticket at LabCentral Boston (worth $50,000). This opportunity by LabCentral Ignite (Sponsored by Amgen, Bristol Myers Squibb, Novartis, Pfizer, Silicon Valley Bank, Takeda, AliraHealth, Eisner Amper and Wilson Sonsini) was awarded to companies with high-impact, innovative science solving problems for human health who are traditionally underrepresented in the industry in addition to providing HDAX with access to LabCentral’s network and resources as a LabCentral Ignite fellow.
Our LinkedIn spotlight can be found here.
BI External Innovation Day – October 26 2023
CEO and Cofounder, Dr. Nabanita Nawar, was the winner of The 2023 Boehringer Ingelheim External Innovation Day. After a fierce competition among nearly a dozen promising biotech companies selected by Boehringer Ingelheim Venture Fund (BIVF) & Boehringer Ingelheim Fremont, HDAX Therapeutics was titled the winner of the External Innovation Day, and also the Audience Choice Award! The day was filled with insightful panel discussions, a CEO round table, and networking opportunities with industry leaders.
This significant validation by Boehringer Ingelheim Venture Fund, Boehringer Ingelheim Research Beyond Borders, BD&L, and esteemed VC judges highlights the potential of our technology, further propelling our momentum and securing $50K in non-dilutive support. We express our gratitude to Boehringer Ingelheim for this golden opportunity!